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Figure S1. Identification of hDNA2 ubiquitination sites using liquid chromatography with 
tandem mass spectrometry (LC-MS/MS). 3xFlag-hDNA2 was isolated from 293T cells expressing 
3xFlag-hDNA2, myc-hTRAF6, and 6His-ubiquitin; resolved by SDS-PAGE; and analyzed using LC-
MS/MS. Ubiquitinated peptides were found using MaxQuant software. Mass spectrometry results for 
fragments of ubiquitinated K29, K194, K275, K303, K377, and K434 residues are shown. Asterisks 
(*) indicate ubiquitinated lysine residues. b and y ions are indicated in blue and red, respectively.
Figure S2. Nuclear localization of WT and hDNA2 mutants. Vectors encoding 3xFlag-
tagged WT, K29R, K194R, K275R, K303R, or K434R hDNA2 were co-transfected with empty 
vectors or vectors encoding myc-hTRAF6 in 293T cells. 3xFlag-hDNA2 proteins in the CE 
and NE were analyzed by western blot analysis using an anti-Flag antibody. GAPDH and 
histone H3 were used as markers for the cytoplasmic and nuclear fractions, respectively.
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Figure S3. Confirmation of knockdown efficiency using quantitative RT-PCR. 
Relative levels of (A) hDNA2 and (B) hTRAF6 mRNA were measured in HeLa cells 
transfected with a control shRNA plasmid (shControl) or shRNA plasmids against 
hDNA2 or hTRAF6, respectively. Total RNA was extracted from these cells and 
quantitative RT-PCR was used to quantify the levels of hDNA2, hTRAF6, and control β-
actin mRNA. hDNA2 and hTRAF6 mRNA levels were normalized to β-actin mRNA 
levels, and the normalized hDNA2 and hTRAF6 mRNA levels in shControl cells was 
arbitrarily set to 1. The values shown are the means ± s.e.m. of three independent 
assays.
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Figure S4. Representative immunofluorescence (IF) staining for pRPA (S33). HeLa 
cells were pretreated with (A) DMSO or C25-140 (30 μM, 48 h) or (B) a control or T6PD 
peptide (100 μM, 24 h). The cells were then treated with DMSO or CPT (1 μM, 4 h). In 
each case, red: pRPA (S33), blue: DAPI-stained nuclei.
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Figure S5. Schematic of the CRISPR/Cas9 D10A double-nicking-based DR-
GFP reporter HDR assay. A cassette containing two CRISPR/CAS9 target sites 
(underlined) was inserted into the GFP gene (GFP-). Expression of Cas9 D10A 
nickase and a pair of single strand guide sequences (sgRNA1 and sgRNA2) 
results in a DSB. DNA end resection and subsequent recombination with a 
downstream GFP fragment (iGFP) will produce a functional GFP gene whose 
product can be detected and quantified using flow cytometry.
